Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X by JAMA Oncology, adding:
“Numerous studies on benefits of GLP1s. Makes sense since obesity underpins so many disease processes including cancer.
Feeling torn – part of me thinks I should be learning to prescribe (can we?), but other part still feels reluctance in outsourcing lifestyle changes to drugs?”
Quoting JAMA Oncology‘s post:
“Most viewed this week from JAMA Oncology: Glucagon-like peptide-1 receptor agonists (GLP1s) are associated with a reduced overall cancer risk in adults with obesity, lowering the risk for endometrial, ovarian, and meningioma cancers.”
Title: GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Authors: Hao Dai, Yongqiu Li, Yao An Lee, Ying Lu, Thomas J. George, William T. Donahoo, Kelvin P. Lee, Harikrishna Nakshatri, John Allen, Yi Guo, Ramon C. Sun, Jingchuan Guo, Jiang Bian
Read the Full Article in Jama Oncology.
More posts featuring Nina Niu Sanford on OncoDaily.